You don’t want to miss the upcoming Pharma Europe 2021 virtual event held on October 11 – 22. This year’s theme: An industry awakened. Where pharma’s potential is unleashed.
As a proud gold sponsor of the event, Anju Software will host a session titled Empower Your MSLs With the Power of Data on Tuesday, October 19 at 11:15 AM CET as a part of the Medical Affairs – The New Face of Field Medical learning module.
During this presentation, Anju Software’s Solutions Specialist Elke Ydens will discuss:
- How the full picture of integrated data is a game changer for your MSL team to execute strategies faster and more effectively
- Managing your key thought leader relationships with user-level custom insights and personalize your engagements
In addition to the session, Elke, along with other medical affairs thought leaders, will participate in a live Q&A at 11:45 AM CET where attendees will have the opportunity to ask questions about case studies and get the speakers’ views on the future.
This is an event you don’t want to miss! For more information and to register click here.
About Reuters Events Pharma 2021
We’ve entered a new era. One where being risk averse is the riskiest strategy, long-established operating models have been torn up and reimagined, and where investment into digital innovation – both culturally and financially – has ignited.
Your challenge now? Scale, widen and hone this transformational potential or fall behind rapidly evolving customer and patient need. Digital must be embedded into every facet of your organisation; enterprise data infrastructure, AI and advanced analytics must dictate each stakeholder interaction; and “patient centricity” must become obsolete – so ingrained into your organisation’s every action that it is subconscious.
Join thousands of your peers at the world’s gathering for pharma pioneers and health innovators – Reuters Events Pharma 2021 (formerly eyeforpharma Barcelona) – the biggest, most senior and cross-functional commercial pharma event.
We may be in the year of the vaccine, but we’re just beginning the decade of pharma’s awakening.